The Journal of Clinical Psychiatry
January 18, 2022
Dan Grossman, Peter S. Hendricks
A research on classic psychedelic–assisted treatments continues to expand, we can expect that findings will sometimes challenge or elucidate long-held conventional beliefs about the purported dangers of these substances. One such notion has been that they precipitate suicidality1 and other self-harm behaviors (eg, jumping off of buildings believing one can fly, walking in front of traffic2) in...
Psychopharmacology
January 15, 2022
Adrian Hase, M Erdmann, Verena Limbach et al.
33 citations
Abstract Rationale and objectives Differences among psychedelic substances regarding their subjective experiences are clinically and scientifically interesting. Quantitative linguistic analysis is a powerful tool to examine such differences. This study compared five psychedelic substance report groups and a non-psychedelic report group on quantitative linguistic markers of psychological states...
Progress in Palliative Care
January 2, 2022
A. C. Garcia, L. O. Maia
The healthcare field and society at large are witnessing a resurgence of interest in the effects and applications of psychedelic therapies in a wide range of settings. In the 1950s and 1960s, research was conducted to explore different applications for psychedelics, such as lysergic acid diethylamide (LSD) and mescaline, in the healthcare setting. However, psychedelic research was dramatically...
2022
Nadia R. P. W. Hutten
Chapter 2Cocaine enhances figural, but impairs verbal 'flexible' divergent thinking 15 Chapter 3 A single dose of cocaine enhances prospective memory performance 43 Chapter 4 Mood and cognition after administration of low LSD doses in healthy volunteers: a placebo controlled dose-effect finding study 65 Chapter 5 Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers...
Novel Psychoactive Substances
2022
A. Potts, S. Thomas, Sl Hill
Abstract 25X-NBOMe compounds are halogenated, phenethylamine-related novel psychoactive drugs, with hallucinogenic and stimulant effects. NBOMes are potent and highly efficacious agonists at the 5HT2a receptor with binding affinities in the low nanomolar range, accounting for their psychoactive and toxic effects. 25I-, 25B-, and 25C-NBOMes are the most frequently encountered compounds; they are...
Psychological Medicine
2022
Wayne Hall
Advocates of the therapeutic use of psychedelic drugs have argued that a promising approach to treatment was prematurely abandoned in the 1960s primarily because of Richard Nixon's 'War on Drugs'.This paper (1) briefly describes research in the 1950s and 1960s in North America on the use of LSD to treat alcohol dependence, anxiety in terminal illness, and anxiety and depression; and (2)...
Psychopharmacology
2022
Nina Schimmers, Joost J. Breeksema, Sanne Y Smith-Apeldoorn et al.
Terminally ill patients may experience existential distress, depression, or anxiety, limiting quality of life in the final stage. Existing psychotherapeutic or pharmacological interventions have (time) limited efficacy. Psychedelic treatment may be a safe and effective alternative treatment option. Systematically review studies on psychedelic treatment with and without psychotherapy for...
Current Topics in Behavioral Neurosciences
2022
Matthew W. Johnson
31 citations
This manuscript reviews research suggesting that classic psychedelics (5-HT2A receptor agonists) are effective in treating addictions including tobacco use disorder. I review historical research from the 1950s to 1970s suggesting that classic psychedelics are associated with addiction recovery across pharmacologically distinct drugs of addiction. I then review anthropological reports about...
Proceedings for Annual Meeting of The Japanese Pharmacological Society
2022
Daisuke Ibi
Recently, FDA approved psilocybin, the psychoactive substance found in the magic mushroom, as a "breakthrough therapy" for depression; however, its detailed mechanism remains unknown. Serotonergic psychedelics such as psilocybin and LSD have hallucinatory effect through stimulation of serotonin 5-HT2A receptor (5-HT2A), motivating us to investigate the role of 5-HT2A stimulation in...
Chronic Stress
2022
Sarah Kuburi, Anne-Marie Di Passa, Vanessa K Tassone et al.
14 citations
Preliminary evidence supports the use of psychedelics for major depressive disorder (MDD). However, less attention has been given to the neural mechanisms behind their effects. We conducted a systematic review examining the neuroimaging correlates of antidepressant response following psychedelic interventions for MDD. Through MEDLINE, Embase, and APA PsycINFO, 187 records were identified and 42...